title: Effect of Liraglutide Therapy on Liver Fat Content in Patients With Inadequately Controlled Type 2 Diabetes: The Lira-NAFLD Study.
abstract: BACKGROUND
  Nonalcoholic fatty liver disease is very frequent in type 2 diabetes, with increased risk of further development of liver fibrosis. Animal studies have shown that GLP-1 receptor agonists may reduce liver lipogenesis. However, data in humans are scarce.
  
  
  OBJECTIVE
  To study the effect of liraglutide 1.2 mg/d on liver fat content (LFC) in patients with uncontrolled type 2 diabetes and to evaluate the factors potentially associated with liraglutide-induced modification of LFC.
  
  
  METHODS
  LFC was measured by proton magnetic resonance spectroscopy before and after 6 months of liraglutide treatment in 68 patients with uncontrolled type 2 diabetes mellitus.
  
  
  METHODS
  Liraglutide 1.2 mg/d.
  
  
  METHODS
  Change in LFC.
  
  
  RESULTS
  Treatment with liraglutide was associated with a significant decrease in body weight, HbA1C, and a marked relative reduction in LFC of 31% (P < 0.0001). No significant modification of LFC was observed in a parallel group of patients 6 months after intensification of the antidiabetic treatment with insulin. The reduction in LFC and body weight were highly correlated (r = 0.490; P < 0.0001). In multivariate analysis, the reduction in LFC was independently associated with baseline LFC (P < 0.0001), age (P = 0.010), and reduction in body weight (P < 0.0001), triglycerides (P = 0.019), and HbA1c (P = 0.034). In the patients who had no significant decrease in body weight, no significant reduction in LFC was observed.
  
  
  CONCLUSIONS
  Six months of treatment with liraglutide 1.2 mg/d significantly reduced LFC in patients with inadequately controlled type 2 diabetes and this effect was mainly driven by body weight reduction. Further studies are needed to confirm that this reduction in LFC may significantly reduce fibrosis progression.
authors.affiliation: Departments of Endocrinology-Diabetology.|INSERM CRI 866, F-21000 Dijon, France.
authors.forename: Jean-Michel
authors.initials: JM
authors.lastname: Petit
authors.affiliation: Radiology, and.
authors.forename: Jean-Pierre
authors.initials: JP
authors.lastname: Cercueil
authors.affiliation: Radiology, and.
authors.forename: Romaric
authors.initials: R
authors.lastname: Loffroy
authors.affiliation: Biology, University Hospital, F-21000 Dijon, France; and.|INSERM CRI 866, F-21000 Dijon, France.
authors.forename: Damien
authors.initials: D
authors.lastname: Denimal
authors.affiliation: Departments of Endocrinology-Diabetology.|INSERM CRI 866, F-21000 Dijon, France.
authors.forename: Benjamin
authors.initials: B
authors.lastname: Bouillet
authors.affiliation: Departments of Endocrinology-Diabetology.
authors.forename: Coralie
authors.initials: C
authors.lastname: Fourmont
authors.affiliation: Radiology, and.
authors.forename: Olivier
authors.initials: O
authors.lastname: Chevallier
authors.affiliation: Biology, University Hospital, F-21000 Dijon, France; and.|INSERM CRI 866, F-21000 Dijon, France.
authors.forename: Laurence
authors.initials: L
authors.lastname: Duvillard
authors.affiliation: Departments of Endocrinology-Diabetology.|INSERM CRI 866, F-21000 Dijon, France.
authors.forename: Bruno
authors.initials: B
authors.lastname: Vergès
mesh_terms: D000273:Adipose Tissue / Q000187:drug effects / Q000473:pathology; D000328:Adult; D000368:Aged; D003924:Diabetes Mellitus, Type 2 / Q000150:complications* / Q000188:drug therapy; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000069450:Liraglutide / Q000008:administration & dosage / Q000627:therapeutic use*; D009682:Magnetic Resonance Spectroscopy / Q000379:methods; D008297:Male; D008875:Middle Aged; D065626:Non-alcoholic Fatty Liver Disease / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology / Q000503:physiopathology; D011379:Prognosis; D011446:Prospective Studies; D015431:Weight Loss / Q000502:physiology
chemical_list: D007004:Hypoglycemic Agents; D000069450:Liraglutide